Biovail Hits Paddock With 2nd Suit Over Aplenzin ANDA

Law360, New York (April 16, 2010, 2:05 PM EDT) -- For the second time in a little over a month, Biovail Laboratories International SRL has launched a suit accusing Paddock Laboratories Inc. of infringing six patents through its plan to market a generic version of antidepressant Aplenzin.

Biovail lodged its latest complaint Thursday in the U.S. District Court for the District of Minnesota, in response to Paddock's third Paragraph IV certification letter sent to Biovail on April 7 stating that Biovail's patents covering Aplenzin are invalid, unenforceable and will not be infringed by the commercial manufacture,...
To view the full article, register now.